Brief: Ultragenyx Announces First Patient Dosed In Pivotal Phase 3 Aspire Study Evaluating Gtx-102 In Angelman Syndrome
19/12/2024 21:07
Dec 19 (Reuters) - Ultragenyx Pharmaceutical Inc
RARE.O :
* ULTRAGENYX ANNOUNCES FIRST PATIENT DOSED IN PIVOTAL PHASE
3
ASPIRE STUDY EVALUATING GTX-102 IN ANGELMAN SYNDROME
* ULTRAGENYX PHARMACEUTICAL INC - PRIMARY ENDPOINT IS
IMPROVEMENT
IN COGNITION ASSESSED BY BAYLEY-4
Source text: ID:nGNX80hQ5f
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx